Merck Animal Health Announces Expansion of NOBIVAC® NXT Platform with the First and Only RNA-Particle Technology Vaccine for Feline Leukemia Virus
Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., ...
Daily23h
Merck gets positive EU CHMP opinions for Keytruda regimens for patients with two types of Gynecologic cancers
Rahway: Merck, known as MSD outside of the United States and Canada, has announced that the European Medicines Agency's ...
dvm3609h
New vaccine protects against feline leukemia virus
The technological innovation is an expansion of the NOBIVAC NXT platform, and a breakthrough achievement against one of the ...
Transgene to Report Major Clinical Data before the end of 2024 – Confirmed Financial Visibility until Q4 2025
First signs of clinical benefit in adjuvant head and neck cancer reported at AACR 2024, paved the way for the start of Phase II part of randomized Phase I/II clinical trial in Q2 2024 – Median ...
Le Lézard16h
Spine BioPharma, Inc. Announces Completion of Enrollment for Phase 3 Clinical Trial of SB-01 to Address Chronic Low Back Pain
Spine BioPharma, Inc., a development stage company committed to non-opiate, non-surgical therapies for Degenerative Disc Disease (DDD), today announced the completion of enrollment of its U.S. Phase 3 ...